Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States
With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years.
Authors
- Zahra Mahmoudjafari (ORCID: https://orcid.org/0000-0002-3168-2521)
- Anthony Masaquel
- Hélène Parisé (ORCID: https://orcid.org/0009-0006-4976-904X)
- Katalin Bognar (ORCID: https://orcid.org/0000-0001-8357-8569)
- Eric Bercaw (ORCID: https://orcid.org/0009-0000-6471-9936)
- Jia Li (ORCID: https://orcid.org/0000-0002-9278-0862)
- Si‐Tien Wang (ORCID: https://orcid.org/0000-0003-1537-7110)
Institutions
- University of Kansas (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1080/13696998.2025.2486839
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09